(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 25.01% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.73%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.88%.
Alvotech's revenue in 2026 is $494,608,000.On average, 8 Wall Street analysts forecast ALVO's revenue for 2026 to be $240,444,729,227, with the lowest ALVO revenue forecast at $226,243,411,114, and the highest ALVO revenue forecast at $252,633,599,245. On average, 8 Wall Street analysts forecast ALVO's revenue for 2027 to be $286,913,012,085, with the lowest ALVO revenue forecast at $248,829,929,620, and the highest ALVO revenue forecast at $343,561,285,038.
In 2028, ALVO is forecast to generate $347,339,977,471 in revenue, with the lowest revenue forecast at $282,192,322,673 and the highest revenue forecast at $416,048,666,308.